Table 2.
Treatment response between patients treated with immune checkpoint inhibitors combined with multitarget tyrosine kinase inhibitors.
| PD-1 Inhibitors + Sorafenib (N = 49) † |
PD-1 Inhibitors + Lenvatinib (N = 39) ‡ |
p | PD-1 Inhibitors + Sorafenib (N = 49) † |
PD-1 Inhibitors + Lenvatinib (N = 39) ‡ |
||
|---|---|---|---|---|---|---|
| mRECISTN (%) |
mRECISTN (%) |
RECISTN (%) |
RECISTN (%) |
p | ||
| Response | 0.827 | 0.703 | ||||
| CR | 2 (4.08) | 1 (2.56) | 0 (0) | 0 (0) | ||
| PR | 7 (14.29) | 8 (20.51) | 8 (16.33) | 8 (20.51) | ||
| SD | 5 (10.20) | 7 (17.95) | 6 (12.24) | 8 (20.51) | ||
| PD | 21 (42.86) | 18 (46.15) | 21 (42.86) | 18 (46.15) | ||
| Not evaluable | 14 (28.57) | 5 (12.82) | 14 (28.57) | 5 (12.82) | ||
| ORR | 9 (18.37) | 9 (23.08) | 0.944 | 8 (16.33) | 8 (20.51) | 0.948 |
| DCR | 14 (28.57) | 16 (41.03) | 0.561 | 14 (28.57) | 16 (41.03) | 0.561 |
PD-1 inhibitors, programmed cell death protein-1 inhibitors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified Response Evaluation Criteria in Solid Tumors. † Of the 14 subjects not available for response assessment, 13 patients died before the first radiologic evaluation and 1 patient was lost to follow-up. ‡ Of the 5 subjects not available for response assessment, 5 patients died before the first radiologic evaluation.